Summary
Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd is a healthcare service provider that discovers, develops, manufactures, and commercializes prescription and over the counter pharmaceutical products for the treatment of iron replacement therapy. The company offers products for treatment of iron deficiency, a range of non prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma’s clinical programs concentrates on safety and efficacy of Broncho Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and uro vaxom for recurrent urinary tract infections. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.
Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Relypsa Secures USD2.6 Million in Venture Funding 12
Relypsa Raises US$80 Million In Series C Financing 13
Relypsa Secures USD62.4 Million in Venture Funding 15
Partnerships 16
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 16
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 17
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 18
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19
Licensing Agreements 20
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 20
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 21
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 22
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 23
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 24
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 25
Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 28
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 29
Equity Offering 30
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 30
Relypsa Raises USD172 Million in Public Offering of Shares 31
Relypsa Completes Public Offering Of Shares For US$101.2 Million 33
Relypsa Completes IPO For US$86.7 Million 35
Acquisition 37
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 37
Relypsa May Sell Itself 39
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 40
Vifor Pharma AG - Key Competitors 41
Vifor Pharma AG - Key Employees 42
Vifor Pharma AG - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 45
Financial Announcements 45
Aug 08, 2017: Vifor Pharma Reports Strong H1 2017 Results And Raises Guidance 45
Corporate Communications 46
Oct 06, 2016: Galenica: New Management at Vifor Pharma and new Galenica Group CFO designated 46
May 10, 2016: Vifor Pharma appoints Colin Bond as Chief Financial Officer 47
Government and Public Interest 48
Feb 20, 2017: Vifor Pharma and ECCO Announces One-Year Research Grant for Iron Deficiency 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49
List of Tables
Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Deals By Therapy Area, 2011 to YTD 2017 9
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Relypsa Secures USD2.6 Million in Venture Funding 12
Relypsa Raises US$80 Million In Series C Financing 13
Relypsa Secures USD62.4 Million in Venture Funding 15
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 16
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 17
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 18
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 19
Vifor Pharma Enters into Licensing Agreement with Akebia Therapeutics 20
Vifor Pharma Expands Licensing Agreement with ChemoCentryx 21
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 22
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 23
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 24
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 25
Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 27
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 28
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 29
Akebia Therapeutics Raises USD50 Million in Private Placement of Shares 30
Relypsa Raises USD172 Million in Public Offering of Shares 31
Relypsa Completes Public Offering Of Shares For US$101.2 Million 33
Relypsa Completes IPO For US$86.7 Million 35
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 37
Relypsa May Sell Itself 39
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 40
Vifor Pharma AG, Key Competitors 41
Vifor Pharma AG, Key Employees 42
Vifor Pharma AG, Other Locations 43
Vifor Pharma AG, Subsidiaries 43
List of Figures
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
